Table 3.
Summary of outcomes reported for chemotherapy regimens used in the clinical trials for locally advanced or metastatic squamous carcinoma of the penis.
| Paper | VinCaP | Pagliaro et al.10 | Di Lorenzo et al.4 | Haas et al.17 | Nicholson et al.9 |
|---|---|---|---|---|---|
| Drugs | Vinflunine | Paclitaxel, cisplatin, ifosfamide | Cisplatin, 5FU | Cisplatin, methotrexate, bleomycin | Docetaxel, cisplatin, 5FU |
| Trial Population | Metastatic; inoperable locally advanced | Locally advanced | Metastatic; inoperable locally advanced | Locally advanced and metastatic | Locally-advanced and metastatic |
| PFS/TTP (95% CI) | 2.9 months (1.4–6.4) | 8.1 months (5.4–50) | 20 weeks (11–20) | 14 weeks (10–21) | 7.1 months (2.7–ULNR) |
| OS | 8.4 months (3.2–14.1) | 17.1 months (10.3–>60) | 8 months (7–12) | 28 weeks (25–35) | 13.9 (6.1–ULNR) |
| ORR | 27.3% | 50% | 32% | 32.5% | 38.5% |
| pCR | 0 | 10% | 0 | 12.5% | 7.6% |
PFS progression-free survival, TTP time to progression, CI confidence interval, OS overall survival, ORR overall response rate, pCR pathological complete remission, ULNR upper limit not reached.